Global reinsurer SCOR is collaborating with cancer-focused medical specialist Wamberg Genomic Advisors on personalized cancer programs for life insurance clients and policyholders.
Cancer Guardian was developed by WGA to provide specialised services not typically made available or covered by health insurance.
The product gives its members access to features and benefits such as Hereditary Risk Screening Test; Dedicated Cancer Support Specialist; Comprehensive Genomic Profiling; On-site Nurse Advocate; and Clinical Trial Explorer.
“We are excited to bring this personalized cancer product to our life insurance clients and their policyholders,” said Michael Colannino, Executive Vice President, U.S. Markets, Growth and Development of SCOR Global Life in the US.
“Cancer is a leading cause of death in the U.S., but it can be prevented or treated if it is caught early.
“We believe that WGA’s Cancer Guardian™ can help achieve that by providing policyholders with valuable information to help them gain knowledge, navigate treatment options and positively impact their longevity.”
Tom Wamberg, CEO of WGA, said that the initiative with SCOR is “an important part of our strategy for expanding Cancer Guardian’s reach.”
“Personalized medicine is filled with promise but is currently moving at a pace that is faster than the ability of our healthcare system to change,” he said.
“The Cancer Guardian product is a new approach to bring state of the art, proactive, genomic medicine to healthy individuals for prevention, as well as serving newly diagnosed patients throughout the continuum of cancer care, in order to better prevent, diagnose, and treat the disease.
“Working with SCOR and their clients will make the significant benefits of personalized medicine available to many more people and save lives in the process.”
